Fremanezumab for preventing migraine

2nd September 2020 by Dr Louise Hudman

Fremanezumab for preventing migraine

This is a new guideline from NICE advising that we can use fremanezumab for preventing migraine in selected populations. It was published in June 2020.

It can be used if:

  • the migraine is chronic ie 15 or more headache days each month for at least 3 months, with at least 8 of those days having features of migraine AND
  • at least three preventative drugs have failed AND
  • it is provided according to the commercial agreements with the company.

It should be stopped if it does not reduce migraine frequency by 30% after 12 weeks of treatment.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"Thank you for many years of help and support in an increasingly difficult job as a sessional GP in the NHS."

Dr Bettina James

See the full list of features within our NASGP membership plans

Membership